HELP TAKE YOUR PATIENTS WITH
ADULT CHRONIC IMMUNE THROMBOCY TOPENIA
FROM REPEATED RELAPSE
TO LONG-TERM RESPONSE
Indication
PROMACTA is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older
with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids,
immunoglobulins, or splenectomy.
Limitation of Use
PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition
increase the risk for bleeding.
Important Safety Information for PROMACTA ® (eltrombopag)
WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C
In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the
risk of hepatic decompensation. (See Section 5.1 of the full Prescribing Information for additional information).
RISK OF HEPATOTOXICITY
PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic
function and discontinue dosing as recommended. (See Section 5.2 of the full Prescribing Information for
additional information).